Changes in brain catecholamine levels following DL-dopa are not potentiated by deuterium substitution.
Adult male Wistar rats were treated with either DL-dopa, D3-DL-dopa or vehicle and sacrificed at various time intervals after treatment. Brain dopamine and noradrenaline concentrations were measured using quantitative mass spectrometric analysis. After treatment with DL-dopa or D3-DL-dopa, total dopamine levels increased above control values; however, no differences were observed between the two drug treatments. Total noradrenaline levels were not significantly altered by treatment with either DL-dopa or D3-DL-dopa. Deuterium substitution did not appear to affect catecholamine deamination or beta-hydroxylation in vivo.
D000818:Animals; D001545:Benserazide / Q000494:pharmacology; D001921:Brain / Q000378:metabolism*; D002395:Catecholamines / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D003903:Deuterium / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D013058:Mass Spectrometry; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains
D002395:Catecholamines; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D003903:Deuterium; D004298:Dopamine; D009638:Norepinephrine